Benzinga | Aug 4, 2021 05:23AM EDT

Piper Sandler Downgrades Alnylam Pharmaceuticals to Neutral, Announces $181 Price Target

Piper Sandler analyst Edward Tenthoff downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Overweight to Neutral and announces $181 price target.